CurrentRheuma
Get Weekly

General medical journalCurrentRheuma coverage

The Lancet

What CurrentRheuma has captured from this journal. The coverage figures describe CurrentRheuma's coverage, not the journal's output. Figures as of 14 November 2026.

CurrentRheuma holds 20 Briefs from The Lancet, most often randomized controlled trials and cohort studies.

Recent
0 Briefs
past 90 days
Archive
20 Briefs
research published Oct 2025 – Jun 2026, Jan–Mar 2025, Jul–Sep 2024 and Jan 2023 – Mar 2024
Editorial
–
no Weekly issue published yet

Topics

Evidence types

Shares are of the 20 Briefs CurrentRheuma has covered from Lancet, by primary topic and study type.

Publication activity

Latest from The Lancet

All coverage, newest first

  1. Lancet

    Efficacy and safety of the CD40 ligand inhibitor dapirolizumab pegol in systemic lupus erythematosus (PHOENYCS GO): a randomised, double-blind, placebo-controlled, phase 3 trial

    Randomized controlled trialLupus & APS

  2. Lancet

    Enpatoran, a Toll-like receptor 7/8 inhibitor, in moderate-to-severe systemic lupus erythematosus: findings from Cohort B of a multicentre, international, double-blind, placebo-controlled dose-finding phase 2 trial

    Randomized controlled trialLupus & APS

  3. Lancet

    Efficacy and safety of LEVI-04 in patients with osteoarthritis of the knee: a randomised, double-blind, placebo-controlled, phase 2 trial

    Randomized controlled trialOsteoarthritis

  4. Lancet

    Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: a case series in China

    Cohort studyLupus & APS

  5. Lancet

    Efficacy and safety of nipocalimab in patients with moderate-to-severe Sjögren's disease (DAHLIAS): a randomised, phase 2, placebo-controlled, double-blind trial

    Randomized controlled trialSjögren's & overlap

  6. Lancet

    Impact of SARS-CoV-2 spike antibody positivity on infection and hospitalisation rates in immunosuppressed populations during the omicron period: the MELODY study

    Cohort studyAcross diseases

  7. Lancet

    Stopping of adalimumab in juvenile idiopathic arthritis-associated uveitis (ADJUST): a multicentre, double-masked, randomised controlled trial

    Randomized controlled trialPediatric

  8. Lancet

    Efficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial

    Randomized controlled trialMyositis

  9. Lancet

    Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study

    Randomized controlled trialSjögren's & overlap

  10. Lancet

    Self-guided digital behavioural therapy versus active control for fibromyalgia (PROSPER-FM): a phase 3, multicentre, randomised controlled trial

    Randomized controlled trialFibromyalgia & pain

  11. Lancet

    Telerehabilitation consultations with a physiotherapist for chronic knee pain versus in-person consultations in Australia: the PEAK non-inferiority randomised controlled trial

    Randomized controlled trialOsteoarthritis

  12. Lancet

    Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial

    Randomized controlled trialRA

  13. Lancet

    Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial

    Randomized controlled trialRA

  14. Lancet

    Methotrexate to treat hand osteoarthritis with synovitis (METHODS): an Australian, multisite, parallel-group, double-blind, randomised, placebo-controlled trial

    Randomized controlled trialOsteoarthritis

  15. Lancet

    Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial

    Randomized controlled trialPediatric

  16. Lancet

    Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK

    Cohort studyAcross diseases

  17. Lancet

    Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)

    Randomized controlled trialLupus & APS

  18. Lancet

    Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)

    Randomized controlled trialLupus & APS

  19. Lancet

    Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)

    Randomized controlled trialSpondyloarthritis & PsA

  20. Lancet

    Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)

    Randomized controlled trialSpondyloarthritis & PsA